Teva Pharmaceutical Industries (TEVA) Income from Non-Controlling Interests: 2009-2025
Historic Income from Non-Controlling Interests for Teva Pharmaceutical Industries (TEVA) over the last 15 years, with Sep 2025 value amounting to $1.0 million.
- Teva Pharmaceutical Industries' Income from Non-Controlling Interests fell 97.87% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.0 million, marking a year-over-year increase of 98.45%. This contributed to the annual value of -$320.0 million for FY2024, which is 471.43% down from last year.
- Teva Pharmaceutical Industries' Income from Non-Controlling Interests amounted to $1.0 million in Q3 2025, which was down 83.33% from $6.0 million recorded in Q1 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Income from Non-Controlling Interests registered a high of $47.0 million during Q3 2024, and its lowest value of -$280.0 million during Q1 2024.
- In the last 3 years, Teva Pharmaceutical Industries' Income from Non-Controlling Interests had a median value of -$14.0 million in 2024 and averaged -$36.9 million.
- Data for Teva Pharmaceutical Industries' Income from Non-Controlling Interests shows a peak YoY increase of 487.50% (in 2024) and a maximum YoY decrease of 1,550.00% (in 2024) over the last 5 years.
- Over the past 5 years, Teva Pharmaceutical Industries' Income from Non-Controlling Interests (Quarterly) stood at $7.0 million in 2021, then plummeted by 557.14% to -$32.0 million in 2022, then skyrocketed by 112.50% to $4.0 million in 2023, then crashed by 1,550.00% to -$58.0 million in 2024, then crashed by 97.87% to $1.0 million in 2025.
- Its last three reported values are $1.0 million in Q3 2025, $6.0 million for Q1 2025, and -$58.0 million during Q4 2024.